Suppr超能文献

慢性钙调磷酸酶抑制剂肾毒性——切莫遗忘。

Chronic calcineurin inhibitor nephrotoxicity-lest we forget.

机构信息

Centre for Transplant and Renal Research, University of Sydney, Westmead Hospital, Westmead, NSW, Australia.

出版信息

Am J Transplant. 2011 Apr;11(4):693-7. doi: 10.1111/j.1600-6143.2011.03504.x.

Abstract

Calcineurin inhibitor (CNI) nephrotoxicity was recognized in Cambridge in the late 1970s. The vasoconstrictor impact of cyclosporine (CsA) and to a lesser extent tacrolimus, in both acute and chronic settings, results from a decrease in vasodilators and increase in vasconconstrictors while direct tubular toxicity results from blockade of mitochondrial permeability transition pores and inhibition of prolyl isomerase. A biopsy of native kidneys of recipients of CNIs reveals nephrotoxicity as the most common pathological diagnosis with chronic CNI toxicity and hypertension the primary problems. A long-term study of randomized clinical trials with up to 20 years of follow-up shows inferiority of both renal function and graft survival for continuous CsA compared to either CsA withdrawal or continuous azathioprine and prednisolone. Pathological hallmarks of chronic CNI nephrotoxicity include stripped interstitial fibrosis, arteriolar hyalinosis and glomerular sclerosis, but with the exception of nodular arteriolar hyalinosis the findings are non specific. The model for chronic renal allograft loss must be multifactorial with both immune and nonimmune factors operating dependent upon an individual's risk factors for cell and/or antibody-mediated rejection, CNI nephrotoxicity and recurrent disease. Better outcomes will require early diagnosis and individualization of therapy dependent upon the dominant mechanisms impacting each patient. The revisionist view put forward by some senior, experienced and thoughtful individuals, challenges the concept of chronic CNI nephrotoxicity as an important clinical entity. By implication, the view that appears to be promoted is as follows: we need not fear-prolonged exposure to CNIs, and in seeking better long-term solutions for transplant recipients, we have forgotten alloimmunity. It is thus apparent that we must revisit the data and again question the basis for chronic CNI nephrotoxicity in current clinical practice. This contribution to the debate will focus on the evidence that CNIs are nephrotoxic and that their impact needs to be limited if we are to improve long-term outcomes after transplantation, leaving others to promote the contrary perspective and perhaps also to reflect on the largely unproven impact of the steroid avoidance and other minimization strategies so prevalent today.

摘要

钙调磷酸酶抑制剂 (CNI) 肾毒性于 20 世纪 70 年代末在剑桥被发现。环孢素 (CsA) 和他克莫司在急性和慢性环境中都具有血管收缩作用,这是由于血管扩张剂减少和血管收缩剂增加所致,而直接的肾小管毒性则是由于阻断线粒体通透性转换孔和抑制脯氨酰异构酶所致。对接受 CNI 的患者的原生肾脏进行活检显示,肾毒性是最常见的病理诊断,慢性 CNI 毒性和高血压是主要问题。一项长达 20 年随访的随机临床试验的长期研究表明,与 CsA 持续使用相比,CsA 停药或持续使用硫唑嘌呤和泼尼松龙,肾功能和移植物存活率均较差。慢性 CNI 肾毒性的病理特征包括剥脱性间质纤维化、小动脉玻璃样变和肾小球硬化,但除结节性小动脉玻璃样变外,这些发现均无特异性。慢性肾移植丢失的模型必须是多因素的,免疫和非免疫因素都依赖于个体发生细胞和/或抗体介导排斥、CNI 肾毒性和复发性疾病的风险因素而发挥作用。更好的结果将需要根据影响每个患者的主要机制,早期诊断和个体化治疗。一些资深、有经验和深思熟虑的人的修正主义观点,对慢性 CNI 肾毒性作为一个重要临床实体的概念提出了挑战。因此,似乎被提倡的观点如下:我们不必担心长期接触 CNI,在为移植受者寻找更好的长期解决方案时,我们已经忘记了同种异体免疫。因此,显然我们必须重新审视数据,并再次质疑当前临床实践中慢性 CNI 肾毒性的依据。这场辩论的贡献将集中在 CNI 具有肾毒性的证据上,如果我们要改善移植后的长期结果,就需要限制其影响,而让其他人来推广相反的观点,并可能也反思目前广泛未经证实的类固醇回避和其他最小化策略的影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验